テネシーにおける食道腺癌の臨床試験
テネシー内の拠点で、食道腺癌に関する13件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07544589Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- University of Tennessee - Knoxville, Knoxville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06203600A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Gastrointestinal Associates, PC, Knoxville
被験者募集中
18歳〜89歳 · 全性別 · 2026/07/01更新 · NCT05530343A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/08更新 · NCT05954312ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。